GT BIOPHARMA INC (GTBP)
US36254L3087 - Common Stock
Which stocks have an unusual volume on Tuesday?
These stocks have an unusual volume in today's session
GT Biopharma Reports Third Quarter 2024 Financial Results
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for...
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...
GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024
GT Biopharma just reported results for the second quarter of 2024.
GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips GT Biopharma (NASDAQ:GTBP) just reported results for the second quarter of 2024...
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3...
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3...
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a...
Why Is Jaguar Health (JAGX) Stock Down 40% Today?
Jaguar Health stock is down on Monday after the company announced plans for a reverse split of JAGX later this week.
Why Is Virios Therapeutics (VIRI) Stock Down 44% Today?
Virios Therapeutics stock is down on Monday after the company announced the pricing for a public offering of VIRI shares today.
Why Is GT Biopharma (GTBP) Stock Up 143% Today?
GT Biopharma stock is up on Monday with heavy trading of GTBP shares despite a lack of news from the biopharmaceutical company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday!
GTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024
GTBP stock results show that GT Biopharma beat analyst estimates for earnings per share the first quarter of 2024.
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650...
GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023
GTBP stock results show that GT Biopharma beat analyst estimates for earnings per share the fourth quarter of 2023.
GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips GT Biopharma (NASDAQ:GTBP) just reported results for the fourth quarter of 2023...
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial...
GT Biopharma announces 1-for-30 reverse stock split (NASDAQ:GTBP)
GT Biopharma announces 1-for-30 reverse stock split to regain compliance with Nasdaq listing requirements.
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company...
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec....
GT Biopharma submits IND to FDA for CD33+ leukemia therapy (GTBP)
GT Biopharma (GTBP) has submitted an Investigational New Drug application to the FDA for GTB-3650 in the treatment of CD33+ leukemia, including AML and MDS. Read more here.
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.
GT Biopharma Reports Second Quarter 2023 Financial Results
Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the day final of trading this week with an overview of the biggest pre-market stock movers on Friday morning!